Morgellons Disease and Lyme: What the Evidence Actually Says

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

About Dr. Kim

Dr. Yoon Hang Kim is a board-certified preventive medicine physician with over 20 years of clinical experience in integrative and functional medicine. He completed the University of Arizona Osher Integrative Medicine Fellowship under Dr. Andrew Weil and holds UCLA medical acupuncture certification. He is a recipient of the IFM Scholarship from the Institute for Functional Medicine. Dr. Kim specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of 8 books and more than 25 peer-reviewed articles.

Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com

Introduction: The Condition No One Wants to Talk About

Few diagnoses in modern medicine carry the stigma that Morgellons disease does. Clients who present with slowly healing skin lesions containing visible filaments — fibers that project from, lie under, or become embedded in the skin — are routinely told they are delusional. That label is often applied reflexively, and many clinicians have come to equate Morgellons with psychogenic illness without examining the primary literature.

That is a problem, because the primary literature has evolved considerably over the past decade.

Morgellons disease (MD) is a dermopathy characterized by spontaneously appearing ulcerative skin lesions containing multicolored filaments, often accompanied by systemic symptoms including fatigue, cognitive difficulties, musculoskeletal pain, and peripheral neuropathy. The modern name was coined in 2002 by Mary Leitao, a biologist and mother seeking answers about her young son's skin symptoms. She borrowed it from a 17th-century letter by Sir Thomas Browne describing children in the Languedoc region of France with "harsh hairs" breaking out on their backs.

What makes the Morgellons conversation clinically relevant today is an accumulating body of research — small but methodologically specific — linking the condition to Borrelia spirochetal infection. If even a subset of Morgellons presentations represent an infectious dermopathy rather than a psychiatric condition, we owe it to our clients to understand the evidence on both sides.

This article examines the primary studies, weighs them against the largest government-sponsored investigation, and considers what all of it means for the integrative clinician who sees complex, multi-system clients every day.

The CDC Investigation: Setting the Baseline

The largest and most widely cited study on Morgellons was published in January 2012 by Pearson et al. in PLoS ONE. Conducted by the CDC in partnership with Kaiser Permanente Northern California (KPNC) and the Armed Forces Institute of Pathology, this descriptive study drew on KPNC enrollees aged 13 and older between 2006 and 2008. The investigators identified 115 cases, of whom 41 underwent full clinical evaluation (Pearson et al., 2012).

The investigators performed comprehensive clinical evaluations, histopathological analyses, and molecular testing. Their headline conclusions were significant:

No common infectious agent was identified across the cohort.
The fibers recovered from skin lesions were predominantly cotton and other common textile materials.
Among the subset who underwent neuropsychological testing, cognitive impairment was found in 23 of 39 assessed.
Clinically significant somatic complaints were reported in 25 of 40 assessed.
The condition was rare in the study population but associated with markedly reduced health-related quality of life.

The study was widely interpreted — and reported — as concluding that Morgellons is a variant of delusional infestation. However, it is worth noting what the authors themselves actually wrote. They described the condition as an "unexplained dermopathy" and explicitly stated that clients experienced real symptoms leading to diminished quality of life. The study encouraged physicians to fully examine these individuals and create treatment plans addressing co-existing conditions, rather than dismissing them outright.

What the CDC study did not do is prove the absence of infection in every presentation. It demonstrated that no single infectious agent was common to all participants it tested. That is a meaningful distinction — though it is worth being precise about what it does and does not imply. The absence of a universal cause does not, by itself, supply positive evidence that an infectious subset exists; it only leaves the question open. That open question is the space in which the Borrelia-focused research operates.

The Borrelia Hypothesis: Molecular and Culture Evidence

The research most directly challenging the "delusional" framing comes from a series of studies led by Marianne Middelveen, a veterinary microbiologist, and Raphael Stricker, an internist affiliated with the International Lyme and Associated Diseases Society (ILADS).

Filament Characterization (2013)

In a foundational study published in Clinical, Cosmetic and Investigational Dermatology, Middelveen et al. used histological observation and electron microscopy to characterize the dermal filaments found in Morgellons lesions. This was a small study — four clients — so its findings characterize those specimens, not every Morgellons presentation. Within those specimens, the filaments were not textile fibers. They were composed of keratin and collagen, arising from the proliferation and activation of keratinocytes and fibroblasts in the epidermis. Spirochetes were also detected in these dermatological specimens (Middelveen et al., 2013).

This was a meaningful challenge to the prevailing narrative. If the fibers in these specimens were human-derived biological structures rather than self-implanted cotton threads, the delusional framework required reconsideration — at least for the subset of presentations that look like this. It is worth noting that even here, the finding that some fibers are biological does not by itself establish that they are disease-specific, that they are produced by Borrelia, or that they cause the client's symptoms. Those are separate questions, each requiring its own evidence.

The 25-Client Study (2015)

The strongest primary study linking Morgellons to Borrelia infection was published in BMC Dermatology in 2015. Middelveen et al. examined 25 Morgellons clients using culture, histology, immunohistochemistry, electron microscopy, PCR, and DNA hybridization — a multi-method approach that is unusual in its rigor for this field (Middelveen et al., 2015).

The authors reported:

All 25 clients demonstrated histological evidence of epithelial spirochetal infection, regardless of their Lyme serological status.
Spirochetes identified as Borrelia strains by PCR and/or in-situ DNA hybridization were detected in 24 of 25 clients.
Viable Borrelia spirochetes were cultured from skin samples in four clients.
Borrelia burgdorferi was cultured from blood in seven clients and from vaginal secretions in three, which the authors interpreted as evidence of systemic infection.

The use of culture is particularly noteworthy. Detecting DNA by PCR demonstrates the organism's presence but not necessarily viability. Culturing live spirochetes from skin and blood is stronger evidence of viable organisms than PCR alone — though Borrelia culture is technically demanding, and these results, too, await independent replication.

Serological and Molecular Confirmation (2018)

A follow-up study published in Clinical, Cosmetic and Investigational Dermatology tested sera from 30 Morgellons clients for antibody reactivity to both the Borrelia burgdorferi group and the relapsing fever Borrelia group of spirochetes. Tissue and body fluid specimens were also tested by PCR (Middelveen et al., 2018).

The findings: 63% of the cohort showed seroreactivity to one or both Borrelia groups. PCR testing was positive in 53%. When serology and PCR results were combined, 90% of clients tested positive for exposure to and/or infection with Borrelia spirochetes.

A critical nuance here: that 90% figure combines exposure (antibodies) with molecular evidence of Borrelia DNA (PCR). PCR demonstrates that genetic material is present; it does not by itself establish that the organism is viable or actively replicating. So the figure does not mean 90% had confirmed active Lyme disease. It also includes relapsing fever Borrelia species — not just B. burgdorferi — which broadens the infectious picture beyond classic Lyme.

The 1,000-Client Cohort: Epidemiological Context

One of the more informative studies for understanding how often Morgellons actually occurs in Lyme clients was published by Fesler, Middelveen, and Stricker in Dermatology Reports in 2018. This study evaluated 1,000 seropositive North American Lyme disease clients for the presence of Morgellons dermopathy (Fesler et al., 2018).

The diagnosis of Morgellons required microscopic detection of fibers in skin lesions or under unbroken skin — an objective criterion, not a self-report. Of the 1,000 Lyme-positive clients, 60 (6%) met criteria for Morgellons. Among those 60:

75% were female.
78% were classified as late disseminated Morgellons under the authors' own staging system — a classification of the Morgellons presentation, not a diagnosis of established late disseminated Lyme disease.
100% were seropositive for B. burgdorferi — though this reflects how the cohort was assembled (it was drawn entirely from Lyme-seropositive clients) and is therefore a selection characteristic, not independent evidence of association.
77% had one or more additional tick-borne coinfections.

The coinfection data is particularly worth noting for integrative clinicians who already think in terms of total infectious burden. Among Morgellons clients, the tick-borne agents broke down as follows: Babesia species were detected in 62%, Bartonella and Rickettsia each in 25%, Ehrlichia in 15%. The study separately noted Helicobacter pylori in 12% — notable, but not a tick-borne organism, and best kept distinct from the coinfection count.

This study reframes Morgellons from a standalone mystery to a potential subset phenomenon within chronic Lyme disease — something that appears in a small but identifiable percentage of clients who are seropositive for Borrelia and often carry additional tick-borne infections as well. The finding that only 6% of this seropositive Lyme cohort met the study's Morgellons criteria raises the question of why. Several candidate explanations are worth holding side by side: host factors such as immune genetics, tissue susceptibility, or biofilm dynamics; differences in exposure or infection history; and more prosaic possibilities like ascertainment and diagnostic heterogeneity. The study did not test these, so none should be presented as established.

Classification, Staging, and the Syphilis Parallel

In 2020, Middelveen et al. proposed an enhanced classification and staging system for Morgellons — a framework put forward by the authors, not an independently validated standard — in Clinical, Cosmetic and Investigational Dermatology, drawing explicit parallels with syphilis — another spirochetal disease with well-characterized dermatological manifestations (Middelveen et al., 2020).

The system builds on a previously established four-class clinical framework (Classes I-IV) and adds severity substages (A, B, C) based on histopathological findings. Stage A lesions show minimal immune infiltrates and negligible tissue disorganization. Stage C lesions demonstrate dense inflammatory infiltrates, macrophage involvement, hemorrhage, and significant cellular disorganization. Stage B falls between.

What makes the syphilis parallel intellectually compelling is the historical irony. Delusional infestation — the diagnosis most commonly applied to Morgellons — was first described by Ekbom in the 1930s. As reported in the 2020 paper (figures I have not independently verified against the original historical sources), three of Ekbom's seven original subjects had documented syphilis, and an earlier French series by Vié reported confirmed syphilis in six of eight clients diagnosed with delusional infestation. The point is suggestive rather than decisive: the very label used to dismiss these clients was first applied to people who turned out to carry an actual spirochetal infection. That said, concurrent infection does not prove the infestation belief was accurate, nor that infection caused the psychiatric picture — infection and neuropsychiatric symptoms can simply coexist.

The researchers also draw attention to bovine digital dermatitis (BDD), a well-established veterinary condition caused by Treponema spirochetes — phylum-level cousins of Borrelia — that produces strikingly similar filamentous lesions in cattle. In BDD, Treponema spirochetes are consistently associated with proliferative, filament-bearing lesions at the skin–hoof junction, and the condition is well characterized in the veterinary literature. The analogy is useful for generating hypotheses: it shows that spirochetal infection can, in at least one mammalian host, drive aberrant keratin and collagen production. But the inference is limited — different organism, different host, different tissue environment. It raises the plausibility of an analogous process in humans with Borrelia infection, and the histological reports from the Middelveen group are consistent with that possibility — though, as discussed below, they await independent confirmation.

The 2016 review by Middelveen and Stricker further proposed a mechanism: Borrelia is known to invade fibroblasts and keratinocytes and to replicate intracellularly. The hypothesis is that intracellular spirochetal infection alters keratin and collagen gene regulation, leading to the aberrant filament production that defines Morgellons. It is worth separating the links in this chain, because the evidence for each is different: that Borrelia can interact with or enter skin cells; that infection changes cellular function; that those changes alter keratin or collagen production; and that the resulting structures explain the characteristic clinical picture. Support for the earlier links does not automatically carry the later ones. The 2016 paper is best read as a mechanistic synthesis, not independent experimental confirmation of the full pathway. The mechanism has not been proven, but it is biologically plausible and consistent with what is known about Borrelia pathophysiology.

Critical Appraisal: What the Evidence Does and Does Not Establish

Intellectual honesty requires that we hold this body of research to the same standards we would apply to any other clinical question. The Borrelia-Morgellons literature makes a stronger case than it is given credit for in mainstream dermatology, but it also has significant limitations.

What the evidence supports:

In selected specimens, Morgellons filaments are not textile fibers. Histological and electron microscopy studies have reported tissue-derived filaments composed of keratin and collagen, produced by activated keratinocytes and fibroblasts — while other investigations, including the CDC study, identified predominantly cellulose (textile) material. The evidence is heterogeneous, and the likeliest reconciliation is that different populations, case definitions, and sampled materials yield different findings without either being wholly wrong.
Borrelia spirochetes have been reported in Morgellons skin specimens by culture, PCR, immunohistochemistry, and DNA hybridization across several studies — largely from a single research group and its collaborating laboratories.
In the largest cohort, approximately 6% of Lyme-seropositive clients met the study's Morgellons criteria.
In the Fesler cohort, most Morgellons clients (77%) had additional tick-borne infections.

What the evidence does not yet establish:

Causation. Detecting an organism in lesional tissue is not the same as proving it causes the lesion. The most useful tests here are not Koch's postulates — a poor fit for a multifactorial human disease — but disease specificity, temporal sequence, independent replication, and evidence that removing or suppressing the proposed cause changes objective pathology. None of these has been met for Borrelia and Morgellons.
Population prevalence of the characterized phenotype. The Borrelia-focused studies use convenience samples, often recruited through patient advocacy organizations or the Morgellons Disease Foundation. The CDC study did estimate prevalence within its defined KPNC population (3.65 per 100,000), so it is not true that no prevalence estimate exists; what is missing is a population-based prevalence for the narrower, histologically characterized phenotype the Borrelia studies emphasize.
Independent replication. Many of the key studies share overlapping authorship — Middelveen and Stricker appear on virtually every major publication. The 2016 review should not be counted as independent confirmation of the 2015 primary study, as the authors acknowledge. Disclosed interests are worth naming specifically rather than lumping together as "ILADS affiliation": in the 2018 molecular study, one author directed the testing laboratory IGeneX and another owned a practice treating tick-borne disease. These disclosures do not invalidate the findings, but they are relevant to how independently the results should be weighed.
Treatment response. If Morgellons is a Borrelia-associated dermopathy, one would expect it to respond to antimicrobial therapy. Case reports suggest some clients improve with antibiotic treatment, but no controlled trial has been published.
The mechanism. The hypothesis that intracellular Borrelia infection alters keratin and collagen gene expression is biologically plausible but unproven.

Selection bias deserves particular attention. Recruiting participants through the Morgellons Disease Foundation and ILADS-affiliated clinics creates a cohort enriched for people who already believe they have an infectious condition and who may have already been diagnosed with Lyme disease. This does not invalidate the molecular findings, but it does limit how broadly the results can be generalized.

Similarly, the CDC study has its own limitations. Its cohort was drawn from a single managed-care organization in Northern California, may not have used the most sensitive testing methods for Borrelia, and its conclusions about fibers being textile material sit uneasily beside the histological findings in later peer-reviewed studies. A word of precision on the testing, since this cuts both ways: two-tier serology is least sensitive early in infection — around the erythema migrans stage — and becomes substantially more sensitive once neurologic, cardiac, or joint manifestations appear, so a negative result is not the weak point in later disease that it is in early disease. The meaningful distinctions to keep separate are early versus established infection, Lyme-group versus relapsing-fever Borrelia, validated clinical assays versus exploratory research methods, and sensitivity versus specificity. The fair criticism of the CDC investigation is not that negative testing carries no weight — it does — but that the study did not conclusively evaluate every proposed infectious subset.

What This Means for the Integrative Clinician

For clinicians practicing integrative and functional medicine, the Morgellons-Lyme conversation is not academic. Many of us see clients with complex multi-system presentations — chronic fatigue, cognitive impairment, widespread pain, autonomic dysfunction, skin manifestations — who have been dismissed by conventional specialists. Some of these clients report skin lesions with fibers. The question is what to do with that presentation.

Several practical considerations follow from the evidence reviewed above:

Do not reflexively diagnose delusional infestation. The peer-reviewed literature now includes histological reports that, in studied specimens, Morgellons filaments were biological structures rather than self-implanted fibers. Whatever the ultimate etiology, calling clients delusional without examining the primary evidence is not evidence-based medicine.

Consider tick-borne infection workup. Given the association data, it is reasonable to consider tick-borne infection in the differential for clients presenting with Morgellons-consistent skin findings. That is different from ordering broad coinfection panels on everyone — the selected cohorts above do not support reflexive screening. Testing earns its place when exposure history, examination, objective lesion characteristics, and the broader clinical pattern point that way, and when the specific assay has interpretable performance characteristics for the question being asked. Where that threshold is met, evaluation for Borrelia infection is appropriate — and not only with the standard two-tier algorithm. Where the clinical picture warrants it, coinfection screening (Babesia, Bartonella, Ehrlichia, Rickettsia) can be considered on the same case-by-case basis.

Consider infectious burden as a working hypothesis. The finding that 77% of Morgellons clients in the Fesler study carried one or more additional tick-borne infections is consistent with a pattern many integrative practitioners already suspect: that chronic illness may reflect the combined effect of multiple pathogens interacting with host susceptibility rather than a single agent. It is worth being honest about the limits of that inference — multiple positive tests document exposure, not cumulative biological activity or causal contribution. "Total infectious burden" is a working hypothesis to be correlated with the clinical picture, not a measured quantity.

Maintain appropriate epistemic humility. The evidence associating Morgellons with Borrelia infection is suggestive, not definitive. We should neither dismiss it nor overstate it. Telling a client that Morgellons is definitively caused by Lyme disease goes beyond what the current data supports, just as telling them it is definitively delusional goes beyond what the CDC study actually proved. The most defensible stance allows several contributors — dermatologic, neurologic, infectious, behavioral, and psychiatric — to coexist in the same client. Compassion does not require deciding prematurely among them, and good medicine rarely does.

Advocate for better research. What this field needs most urgently is an independent, well-designed study with proper controls, population-based sampling, and sensitive Borrelia detection methods. Until that study is done, the conversation will remain polarized between two camps that are each working from incomplete data.

Conclusion

Morgellons disease sits at a frustrating intersection of legitimate science and institutional inertia. The existing literature — limited as it is — provides molecular, histological, and culture evidence that at least some cases of Morgellons are associated with Borrelia spirochetal infection. In the specimens that have been studied, filaments have been shown to be biological structures and Borrelia has been detected by multiple methods. And whatever the ultimate etiology, the clients are suffering.

At the same time, the evidence falls short of proving causation, the studies have significant methodological limitations, and the field needs independent replication from research groups without ties to either the patient-advocacy community or the organizations most invested in the psychiatric framing.

For the integrative clinician, the practical takeaway is this: when a client presents with skin lesions containing visible filaments, the least scientific thing we can do is reach for a psychiatric diagnosis without first examining the tissue, ordering appropriate infectious workups, and reading the primary literature. The most scientific thing we can do is hold space for uncertainty, investigate thoroughly, and treat the person in front of us with both evidence and compassion.

Luck favors the prepared bold — and prepared, in this case, means being willing to read the primary evidence carefully, hold the open questions honestly, and let the strength of each claim match the strength of the data behind it.

Important: This article is for educational purposes only and is not medical advice. Reading it does not establish a physician–client relationship. Anyone with non-healing skin lesions, suspected tick-borne illness, or related symptoms should seek individualized evaluation from a qualified clinician.

References

1. Pearson ML, Selby JV, Katz KA, et al. Clinical, epidemiologic, histopathologic and molecular features of an unexplained dermopathy. PLoS ONE. 2012;7(1):e29908. doi:10.1371/journal.pone.0029908

2. Middelveen MJ, Mayne PJ, Kahn DG, Stricker RB. Characterization and evolution of dermal filaments from patients with Morgellons disease. Clin Cosmet Investig Dermatol. 2013;6:1-21. doi:10.2147/CCID.S39017

3. Middelveen MJ, Bandoski C, Burke J, et al. Exploring the association between Morgellons disease and Lyme disease: identification of Borrelia burgdorferi in Morgellons disease patients. BMC Dermatol. 2015;15:1. doi:10.1186/s12895-015-0023-0

4. Middelveen MJ, Stricker RB. Morgellons disease: a filamentous borrelial dermatitis. Int J Gen Med. 2016;9:349-354. doi:10.2147/IJGM.S116608

5. Fesler MC, Middelveen MJ, Stricker RB. Clinical evaluation of Morgellons disease in a cohort of North American patients. Dermatol Rep. 2018;10(1):7660. doi:10.4081/dr.2018.7660

6. Middelveen MJ, Du Cruz I, Fesler MC, Stricker RB, Shah JS. Detection of tick-borne infection in Morgellons disease patients by serological and molecular techniques. Clin Cosmet Investig Dermatol. 2018;11:561-569. doi:10.2147/CCID.S184521

7. Middelveen MJ, Martinez RM, Fesler MC, et al. Classification and staging of Morgellons disease: lessons from syphilis. Clin Cosmet Investig Dermatol. 2020;13:145-164. doi:10.2147/CCID.S239840

Yoon Hang Kim, MD, MPH, is a board-certified preventive medicine physician practicing integrative and functional medicine. He is the author of MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon, and is the founder of the LDN Support Group. For more clinical articles, visit ifmsynergy.com.